Short answer
OPKO HEALTH, INC. (OPK) filed an 8-K current report with the SEC on April 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 operating and financial results covered quarter ended March 31, 2026.
OPKO HEALTH, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 operating and financial results covered quarter ended March 31, 2026
- Press release includes business update, financial results, and financial guidance
- Investor conference call scheduled to discuss Q1 performance and outlook
- Detailed results and guidance available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $124.2M versus $149.9M, reflecting BioReference asset sales; net loss narrowed to $54.8M from $67.6M
- Diagnostics revenue fell to $72.2M from $102.8M, while operating loss improved over 45% to $13.0M after divestitures and test rationalization
- Pharmaceuticals revenue increased to $52.0M from $47.1M, supported by higher international sales and NGENLA payments of $6.4M
- Cash, equivalents, securities and restricted cash totaled $341.9M; $108.0M remained available under the repurchase authorization
- MDX2301 and MDX2003 entered Phase 1 trials, creating clinical catalysts but exposing investors to early-stage development and regulatory risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OPKO HEALTH, INC. 8-K filings
Get the next OPK 8-K as it lands
Follow OPK for push alerts, or ask the research agent what this filing means.